Do Wall Street’s DGX Ratings Reveal a Durable Edge in Diversified Diagnostics for Quest?

• In recent days, Quest Diagnostics has attracted favorable attention from Wall Street, with analysts issuing 9 buy and 9 hold ratings and no sell calls, reflecting confidence in its broad portfolio of diagnostic testing and healthcare services across the United States.
• This cluster of positive opinions highlights how Quest’s diversified offering and perceived financial resilience are shaping analyst views on its role in an evolving healthcare landscape.
• We’ll now examine how this upbeat analyst sentiment could influence Quest Diagnostics’ investment narrative, particularly its emphasis on diversified diagnostics and execution.

This technology could replace computers: discover 30 stocks that are working to make quantum computing a reality.

Quest Diagnostics Investment Narrative Recap

To own Quest Diagnostics, you have to believe in the long term value of its broad diagnostic portfolio, steady cash generation and role in preventive healthcare. The recent wave of 9 buy and 9 hold ratings reinforces that view but does not materially change the near term balance between growth opportunities in higher value testing and the risk that reimbursement cuts or policy shifts could pressure pricing and volumes.

Among recent announcements, the April 2026 guidance raise, with net revenues now expected at US$11.78 billion to US$11.90 billion and diluted EPS at US$9.58 to US$9.78, feels most connected to the upbeat analyst sentiment, as it underpins confidence in Quest’s execution on advanced testing, partnerships and acquisitions that are central to the current catalyst story.

Yet investors should also be aware that potential changes to Medicare reimbursement and broader healthcare coverage could...

Read the full narrative on Quest Diagnostics (it's free!)

Quest Diagnostics' narrative projects $13.0 billion revenue and $1.4 billion earnings by 2029. This requires 4.9% yearly revenue growth and about a $0.4 billion earnings increase from $1.0 billion today.

Uncover how Quest Diagnostics' forecasts yield a $223.44 fair value, a 9% upside to its current price.

Exploring Other Perspectives

Simply Wall St Community members currently bracket Quest’s fair value between about US$223 and US$318 across 2 independent views, underlining how far opinions can stretch. Against that backdrop, the key risk around possible reimbursement reductions and shifting payer mixes becomes an essential lens for anyone assessing how Quest’s diversified diagnostics business might perform.

Explore 2 other fair value estimates on Quest Diagnostics - why the stock might be worth as much as 56% more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Quest Diagnostics research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Quest Diagnostics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Quest Diagnostics' overall financial health at a glance.

Interested In Other Possibilities?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Find 46 companies with promising cash flow potential yet trading below their fair value.
• AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com